When it comes to preventing cancer, early detection is everything. But with all the noise online—from trendy full-body scans to viral "biohacking" tests—it's easy to miss the tools that are actually proven to save lives. This article cuts through the confusion and focuses on the evidence-based cancer screenings that can make a real difference—and which are worth prioritising.
Table of Contents
- Why Screening Matters (And Where We Go Wrong)
- The South Korea and UK Cautionary Tales
- The Screenings That Are Proven to Save Lives
- A Word on Full-Body MRI Scans
- Public Health vs. Personal Preference
- References
Why Screening Matters (And Where We Go Wrong)
Late-stage cancer diagnoses are one of medicine's most preventable tragedies. A mid-50s patient with three young children diagnosed with stage 4 lung cancer—the kind of case that should never happen when robust screening programs exist—represents exactly the gap between what modern medicine can detect and what the public actually knows.
Robust cancer screening programs can detect cancer long before it causes symptoms—when treatment is most effective. Yet awareness of evidence-based prevention programs remains low, while attention gets captured by trendy, expensive full-body MRI scans. The research points in a different direction.
The programs that are proven to save lives deserve the focus. Understanding both the evidence for proven screenings and the honest assessment of full-body MRIs leads to some conclusions that may surprise many people.
The South Korea and UK Cautionary Tales
The American Cancer Society maintains a list of screening recommendations based on the latest evidence, including a recent, important update [1].
These are the screenings proven to save lives. That qualification is critical. Otherwise, we risk repeating public health disasters—like what happened in South Korea.
In South Korea, thyroid cancer diagnoses exploded. In 1999, there were 6.3 cases per 100,000 people. By 2009, it jumped to nearly 48—more than a 7-fold increase [2].
What happened? Doctors weren't detecting more aggressive cancers. Instead, they were finding more cases that had been there all along, thanks to widespread use of ultrasound funded by a government screening initiative [2].
Earlier detection should lower death rates. But that's not what happened. Thyroid cancer mortality stayed the same [2].
Between 2001 and 2012, thyroid surgeries rose from 1,000 to about 11,000 per year. Yet, no change in mortality was observed [3].
Most of these surgeries were unnecessary. Many of the cancers were so slow-growing they would never cause harm. But surgeries come with real risks—and in this case, no benefit.
A similar pattern emerged in the UK. A massive trial tested screening for ovarian and tubal cancers using blood tests and ultrasounds. The result? No difference in mortality between the screened and unscreened groups. Worse, there were significant numbers of unnecessary surgeries on benign growths [4].
These examples show that more information does not always equal better outcomes. Sometimes, screening can be harmful.
That's why the focus should remain on the few screenings where evidence clearly shows a benefit.
The Screenings That Are Proven to Save Lives
Here is the evidence-based breakdown by cancer type.
Breast Cancer
Women should have the option to begin annual mammograms at age 40, with annual screening recommended from age 45 to 54. At 55 and older, screening can shift to every two years [1].
There is concern online that mammograms might increase cancer risk due to radiation. But the exposure is tiny. A UK analysis projected that regular mammograms save between 150 to 300 lives for every single life lost to radiation exposure [5].
For those with a family history of breast cancer, screening may need to start earlier—a conversation worth having with a doctor.
Cervical Cancer
Screening should begin at age 25 and continue until at least 65. Depending on the test, this should be done every 3 to 5 years [1].
Options include:
- HPV test every 5 years
- Self-collected HPV test every 3 years
- Co-test (HPV + Pap) every 5 years
- Pap test alone every 3 years (if HPV testing isn't available)
Endometrial Cancer
Screening here is not for everyone. But at menopause, all women should be informed about the risks and symptoms. Women with a particular medical history may need annual endometrial biopsies [1].
Prostate Cancer
Prostate cancer screening guidelines often surprise men.
There is no blanket recommendation. Instead, starting at age 50, the decision about whether to screen should be made in conversation with a doctor [1].
Why the caution? Because 1 in 5 men die with prostate cancer, not from it. Many cancers grow so slowly they would never cause harm—closely paralleling the thyroid cancer example from South Korea.
Biopsies and treatments can cause more harm than good in these cases, making shared decision-making essential.
Colorectal Cancer
Colorectal cancer screening applies to everyone.
Screenings should begin at age 45 and continue to age 75, assuming good health [1].
Rates are rising globally, especially among younger adults [6].
A colonoscopy is not the only option. There are now stool-based tests that are highly sensitive to colorectal cancer signs—making it easier than ever to stay on top of this screening [1]. These stool-based options include the fecal immunochemical test (FIT) and multi-target stool DNA tests, which can be done at home without the preparation required for a colonoscopy. Any positive stool test should be followed by a colonoscopy for confirmation.
Lung Cancer
The guidelines here have recently changed.
Screening with low-dose CT (LDCT) is now recommended for people aged 50 to 80 who:
- Currently smoke or used to smoke
- Have at least a 20 pack-year smoking history [1]
A pack-year equals 1 pack per day for 1 year. So 20 pack-years could mean 1 pack per day for 20 years, or 2 packs per day for 10 years.
But this cutoff may soon change.
A recent study found that switching to a 20-year smoking duration criterion (regardless of how many cigarettes per day) could save an additional 30,000 lives over 5 years in the U.S. alone [7].
This new approach is:
- Easier to calculate
- More inclusive
- Likely more effective [8]
Those with a history of smoking—even light smoking over many years—may benefit from screening under this proposed model.
A Word on Full-Body MRI Scans
The promise of full-body MRI scans is seductive: find problems before symptoms start, catch cancer early, gain peace of mind.
But the American College of Radiology recommends against total body screening in people without symptoms or specific risk factors [9].
The reasoning is straightforward:
- There is no evidence these scans improve outcomes or extend life [9]
- They often find non-specific abnormalities, triggering more tests, procedures, and anxiety [9]
This mirrors the South Korea-style situation—finding slow-growing cancers that would never cause harm, but generating surgeries and stress without offsetting benefits.
Public Health vs. Personal Preference
There is an important distinction between population-level guidance and individual decision-making.
For public health, hard data is required. Until full-body MRI screening is proven to save lives at the population level, the risk and cost across a whole population cannot be justified.
For individuals, it is more nuanced.
Some people are comfortable with uncertainty and would prefer to monitor any finding, even if its significance is unclear. Others would be overwhelmed by worry—for them, not knowing may actually be better for their mental and physical health.
So while public health guidelines do not support full-body MRIs, the decision at a personal level can vary—depending on individual preferences and tolerance for risk. Either way, the proven screenings above are the non-negotiable starting point.
References
2. https://www.bmj.com/content/355/bmj.i5745
3. https://www.nejm.org/doi/10.1056/NEJMc1507622
4. https://pubmed.ncbi.nlm.nih.gov/37183782/
6. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00600-4/fulltext
7. https://jamanetwork.com/journals/jama/article-abstract/2841694
